VAV1 gene mutations trigger T-cell tumors in mice

blood cells
Credit: CC0 Public Domain

Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external. White blood cells (WBC) are integral to an organism's immune defenses against disease and invasion; unfortunately, these mechanisms may go awry causing uncontrolled increases in dysfunctional cell numbers, resulting in tumor formation. Now, researchers at the University of Tsukuba have illustrated how mutations in a specific gene called VAV1 may promote tumors involving a type of white blood cell, the T-cell, in experimental mice.

Leukocytes, or WBC, are fundamental to the body's immune function. They include B-lymphocytes that generate antibodies, as well as thymic-lymphocytes or T-cells with diverse immune-related functions, so called because they develop in the thymus gland. T-cell neoplasms include a mature subtype called peripheral T-cell lymphoma. Studies have shown that VAV1, a gene that participates in T-cell receptor signaling, is altered in several peripheral T-cell lymphoma variants; therefore, the research team sought to elucidate the role of VAV1 mutants in the malignant transformation of T-cells in vivo.

The tumor suppressor gene p53 is called guardian of the genome because it prevents genome mutation. The researchers replicated VAV1 mutations found in human T-cell tumors in both normal ("wild-type") mice and mice lacking p53. Lead author Kota Fukumoto describes their findings: "No tumors developed in the wild-type mice with VAV1 mutations over a year of observation; whereas immature tumors developed in mice that lacked p53. Remarkably, mice that both lacked p53 and had mutations in VAV1 developed mature tumors resembling human peripheral T-cell lymphoma, and had poorer prognosis than the mice lacking p53 only."

The team also transplanted tumor cells into mice that lacked a functional thymus. The results suggested that initiation was likely due to mechanisms within the cell itself. "We noted that T-cell tumors with VAV1 mutation showed Myc pathway enrichment, as well as somatic copy number alterations (SCNAs), including at the Myc locus," explains Professor Shigeru Chiba, senior author. Significantly, Myc, a family of regulator genes and proto-oncogenes, and SCNAs, which cause discrepancies in DNA copies, are both distinct hallmarks of .

"Interestingly, pharmaceutical inhibition of the Myc pathway increased overall survival of mice harboring VAV1-mutant tumors," Professor Chiba adds. "Therefore, our methodology and results suggest that the VAV1-mutant expressing mice developed in this study could be a for evaluating therapeutic agents directed against specific T-cell neoplasms."

Explore further

Immune cell steroids help tumours suppress the immune system, offering new immunotherapy targets

More information: Kota Fukumoto et al. VAV1 mutations contribute to development of T-cell neoplasms in mice, Blood (2020). DOI: 10.1182/blood.2020006513
Journal information: Blood

Citation: VAV1 gene mutations trigger T-cell tumors in mice (2020, October 12) retrieved 24 June 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments